Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory

  Robust commercial demand, with softer early-stage demand due to biotech funding constraints Growth project portfolio progressing in line with plan Outlook 2023 reiterated, with high single-digit CER sales growth […]

Weiterlesen

Lonza Completes Expansion of Conjugation Facility in Visp (CH)

Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates The Visp (CH) investment includes two manufacturing suites and supporting infrastructure Additional manufacturing […]

Weiterlesen